Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the effect on gastrointestinal stromal tumour (GIST) patients of the delisting of the drug regorafenib by the Cancer Drugs Fund; and what steps he is taking to ensure that GIST patients have access to appropriate drugs and treatment.

NHS England has advised that the decision to remove regorafenib (Stivarga) for the treatment of gastrointestinal stromal tumour (GIST) from the national Cancer Drugs Fund (CDF) list has been subject to a formal appeal and referred back to the CDF clinical panel for reconsideration. Regorafenib will therefore remain available through the Cancer Drugs Fund until this process is completed and subject to the final outcome.